P1104: A PHASE 1 STUDY EVALUATING SAFETY AND EFFICACY OF PARSACLISIB IN COMBINATION WITH BENDAMUSTINE + OBINUTUZUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA (CITADEL-102)
M. Hamadani,
M. Coleman,
R. Boccia,
J. Duras,
M. Hutchings,
P. L. Zinzani,
R. Cordoba,
M. B. Oreiro,
V. Williams,
M. Stouffs,
P. Langmuir,
J.-M. Sancho
Affiliations
M. Hamadani
1 Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee
M. Coleman
2 Clinical Research Alliance Inc, Westbury
R. Boccia
3 Center for Cancer and Blood Disorders, Bethesda, United States of America
J. Duras
4 Department of Haematooncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czechia
M. Hutchings
5 Department of Haematology and Phase 1 Unit, Rigshospitalet, Copenhagen, Denmark
P. L. Zinzani
6 Institute of Hematology “Seràgnoli”, University of Bologna, Bologna, Italy
R. Cordoba
7 Lymphoma Unit, Department of Hematology, Fundación Jimenez Diaz University Hospital
M. B. Oreiro
8 Instituto de Investigación Sanitaria Gregorio Marañón, Madrid, Spain
V. Williams
9 Incyte Corporation, Wilmington, United States of America
M. Stouffs
9 Incyte Corporation, Wilmington, United States of America
P. Langmuir
9 Incyte Corporation, Wilmington, United States of America
